|
Antibiotic
|
Klebsiella (N = 23)
|
CONS (14)
|
Enterobacter (N = 13)
|
Acinetobacter (N = 8)
|
Escherichia coli (N = 3)
|
Serratia rubidaea (N = 3)
|
|---|
|
R/(R + S)
|
R %
|
R/(R + S)
|
R %
|
R/(R + S)
|
R %
|
R/(R + S)
|
R %
|
R/(R + S)
|
R %
|
R/(R + S)
|
R %
|
|---|
|
Beta-lactam Antibiotics
|
|
Oxacillin
|
6/6
|
100
|
8/10
|
80
|
3/3
|
100
|
2/2
|
100
|
1/1
|
100
|
1/2
|
50
|
|
Cefotaxime
|
19/21
|
90.5
|
4/6
|
66.7
|
10/12
|
83.4
|
6/7
|
85.7
|
3/3
|
100
|
1/3
|
33.3
|
|
Meropenem
|
0/18
|
0
|
4/5
|
80
|
2/10
|
20
|
4/7
|
57.1
|
2/3
|
66.7
|
0/3
|
0
|
|
Pip-Taz
|
4/10
|
40
|
1/2
|
50
|
2/4
|
50
|
3/6
|
50
|
2/2
|
100
|
1/3
|
33.3
|
|
Non-beta-lactam Antibiotics
|
|
Amikacin
|
12/21
|
57
|
5/10
|
50
|
0/1
|
0
|
7/7
|
100
|
3/3
|
100
|
1/3
|
33.3
|
|
Gentamicin
|
15/20
|
75
|
7/12
|
58.3
|
5/13
|
38.5
|
5/7
|
71.4
|
2/3
|
66.7
|
1/3
|
33.3
|
|
Chloramphenicol
|
13/20
|
65
|
5/11
|
45.5
|
8/13
|
61.5
|
7/7
|
100
|
3/3
|
100
|
3/3
|
100
|
|
Ciprofloxacin
|
16/21
|
76.2
|
8/10
|
80
|
5/13
|
38.5
|
3/16
|
18.8
|
3/3
|
100
|
1/3
|
33.3
|
|
Ofloxacin
|
13/18
|
72.2
|
8/12
|
66.7
|
1/12
|
8.3
|
4/6
|
66.7
|
3/3
|
100
|
1/3
|
33.3
|
|
Linezolid
|
–
|
–
|
0/3
|
0
|
–
|
–
|
1/1
|
100
|
–
|
–
|
0/1
|
0
|
|
Vancomycin
|
1/1
|
100
|
0/4
|
0
|
1/1
|
100
|
–
|
–
|
–
|
–
|
0/1
|
0
|
|
Tigecycline
|
2/11
|
18.2
|
–
|
–
|
1/7
|
14.3
|
2/6
|
33.3
|
0/2
|
0
|
0/1
|
0
|
|
Colistin
|
2/18
|
11.2
|
–
|
–
|
1/8
|
12.5
|
1/5
|
20
|
0/3
|
0
|
1/3
|
33.3
|
- CONS Coagulase negative staphylococi, Pip-Taz Piperacillin-Tazobactam, R Number of resistant isolates, R% Percentage of resistant isolates, S Number of susceptible isolates, [−] Not tested
